Research On Tax Compliance Of Listed Companies In China’s Pharmaceutical Manufacturing Industry

The pharmaceutical manufacturing industry is related to the health of all the people and greatly affects the vital interests of the people.Recently,with the expansion of the scale of the listed companies in the pharmaceutical manufacturing industry,the tax revenue is also increasing.In 2018,an excellent film "I’m not the God of medicine" was the first one,which promoted the Ministry of Finance and the State Administration of Taxation to issue preferential policies for anti-cancer drugs.Then,the key word for 2019 is tax reduction.Many preferential policies for pharmaceutical manufacturing enterprises have been issued.With the implementation of this series of "new policies of medical reform",it will further promote the transformation of pharmaceutical manufacturing enterprises,and also bring new challenges to the existing tax management.At present,there are still many problems that need to be solved urgently in the current tax situation of Listed Companies in pharmaceutical manufacturing industry.These problems are mainly manifested in the following aspects: the difficulty of input tax verification,output tax verification,R & D expenditure verification and connected transaction verification.Tax compliance problems are caused by various factors,such as the low compliance consciousness of taxpayers,the imperfect system of tax authorities and the inspection of tax environment.Tax revenue is an important source of financial revenue in China,and tax compliance,as an important indicator of whether enterprises can fulfill their tax obligations in accordance with the tax law,is a problem that has been widely valued by all countries since the establishment of the tax system.Developed countries generally regard promoting tax compliance as the fundamental task of tax authorities,which is the research focus in the tax field of all countries in the world,and has gradually become the focus of our tax reform.In recent years,although the income of China’s pharmaceutical manufacturing industry has grown rapidly,the tax loss is serious,and the tax compliance problem cannot be underestimated.In this context,it is particularly important to study how to improve the tax compliance of listed manufacturing companies in China.It can not only enrich and develop the tax management theory,but also provide countermeasures and references for tax authorities to take measures to improve the monitoring ability of tax collection and management.Study this problem is of important theoretical significance and practical value.In this paper,we study how to improve the tax compliance of pharmaceutical manufacturing listed companies.Firstly,it introduces the research background and significance,collates the relevant domestic and foreign literature.On the basis of summarizing the previous achievements,defines the concept of pharmaceutical manufacturing industry and tax compliance,summarizes the Equity Theory,Expected Utility Theory and Prospect Theory of tax compliance.These studies lay a theoretical foundation for the follow-up research of this paper.Then,it expounds the analysis and problems of tax payment compliance,and summarizes the main problems and the underlying causes of the problems in the current industry from the perspectives of industry characteristics,industry status and tax related situations.In addition,in the aspect of empirical method,the comprehensive coefficient of variation model was constructed.Then,the financial data of 70 companies were put into the formula to calculate the monitoring and warning interval of pharmaceutical enterprises.This paper then calculates the results and explains them reasonably,so that we can deepen our understanding of non-compliance.Finally,on the basis of summarizing the main conclusions and practical enlightenment,this paper explores the ways to reduce non-compliance,discusses the solutions and paths of tax non-compliance.The paper discusses the countermeasures and ways to solve the problem of tax non-compliance,and puts forward the future development prospect based on the development of China’s pharmaceutical manufacturing industry.According to the principle of "starting from the taxpayer’s demand,based on the taxpayer’s satisfaction,and finally the taxpayer’s compliance",the countermeasures and suggestions are summarized from three angles of "taxpayer","taxation authority" and "tax environment",This paper concludes three countermeasures and suggestions.The three suggestions are to build the ethical consciousness of tax paying honestly,to construct a scientific tax management system and to establish a fair tax environment.